Merck & Co. is adding yet another immuno-oncology first under Keytruda’s belt. But the breadth of the win comes out less than ideal. The FDA has backed Keytruda’s use alongside chemotherapy, with or without Roche’s Avastin, for treating patients with persistent, recurrent or metastatic cervical cancer but only for those whose tumors express the PD-L1… Read More »
Centene and Humana filed separate lawsuits against Merck alleging the drugmaker’s “monopolistic scheme” delayed generic versions of its blockbuster cholesterol drug Zetia from coming to market, causing the insurers to pay higher prices for years. The suits by two of the biggest health insurers were filed in similar but separate lawsuits Wednesday in federal court in… Read More »
Merck and Eisai were eager to tout a headline phase 3 win in December for their combination therapy of Keytruda and Lenvima because it involves the regimen’s first FDA-approved indication in endometrial cancer. Now we know how big that win is. Keytruda and Lenvima cut the risk of death by 38% over physician’s choice of… Read More »
As detailed in The Highwire video above, in January 2020, Dr. Julie Gerberding — director of the U.S. Centers for Disease Control and Prevention from 2002 until 2009, who after leaving the CDC became president of Merck’s vaccine division in January 20101 — sold half her Merck stock options for $ 9.11 million. Gerberding also… Read More »